Aleph Farms Unveils Roadmap For Achieving Net Zero Carbon By 2025
Aleph Farms, the first cultivated meat company to grow steaks directly from non-genetically engineered animal cells, today announced its detailed roadmap for achieving net zero carbon. In April 2020, Aleph Farms first announced it would reach net zero within its operations by 2025, and throughout its entire supply chain by 2030. Today, Aleph Farms’ net zero carbon roadmap details its scope for achievement, strategic partnerships and the investments necessary to advance its environmental goals and business bottom line as the company delivers its quality cultivated beef steaks.
“The production of food is one of the largest sources of greenhouse gas emissions on the planet today, and a driving reason why Aleph Farms is making long-term sustainability a top priority,” said Dr. Lee Recht, VP sustainability at Aleph Farms. “Our roadmap represents significant research that will enable us to fulfill our commitment to total net zero within this decade and we strongly encourage other companies within the agrifood ecosystem to work to eliminate their carbon footprint as soon as possible.”
Aleph Farms’ roadmap to net zero carbon was created in partnership with Aimee Christensen, CEO of Christensen Global Strategies and a world-renowned expert in climate change and sustainability strategies. The roadmap to reduce the company’s carbon footprint includes optimized energy efficiency, transitioning renewable energy, offsetting and/or insetting unavoidable remaining emissions via reinvestment in decarbonizing Aleph Farms’ own production lines and supply chains.
“By building a company with a net zero mindset from nearly day one, Aleph Farms is pioneering the smart clean growth that all companies must take,” Christensen said. “By investing in energy efficiency and direct renewable energy supplies and similar strategies within its supply chain, Aleph Farms will benefit their bottom line now and even more in the future as carbon is priced around the world.”
As part of its roadmap, Aleph Farms has also signed a Memorandum of Understanding (MoU) with ENGIE Impact, the sustainability consulting arm of ENGIE. The two companies will work together to ensure Aleph Farms’ operations are net-zero compatible from the get-go, integrating energy efficiency, circularity in energy, as well as renewable energy and other strategic investments across Aleph’s production line and supply chains.
“We are delighted to work with Aleph Farms to support their net-zero strategy and vision to transform the meat industry,” said Nicolas Lefevre-Marton, Managing Director, EMEAI at ENGIE Impact. “We are deeply committed to helping bold organizations of all sizes around the world develop the right decarbonization goals, roadmaps and execution strategies to successfully achieve net-zero.”
In addition, Aleph Farms’ commitment to net zero carbon is being supported by a partnership with CE Delft, to analyze the life cycle impacts of Aleph Farms’ production line and supply chain, identifying hotspots and working to optimize the overall ecological footprint including carbon, water, waste and more. CE Delft recently conducted a study that found cultivated meat has the potential to reduce the carbon footprint of beef production by 92% when utilizing renewable sources of energy.
Aleph Farms is co-hosting an event alongside Food Tank at this year’s COP26 in Glasgow, Scotland on November 9, 2021. The panel, A New Approach to Meat, will discuss what it takes to change the production of animal protein and improve environmental impact while maintaining farmers' livelihoods and food security. The company’s white paper, An Inclusive Transition to a Sustainable and Resilient Meat Sector, highlights how transformational net zero carbon production systems can complement sustainable agricultural practices, supplying nutritional food to the growing population and strengthening global food security. To learn more about Aleph Farms' path to sustainability, please visit aleph-farms.com/sustainability.
About Aleph Farms
Aleph Farms grows beef steaks, from non-genetically engineered, non immortalized cells isolated from a living cow, without slaughtering the animal and with a significantly reduced impact to the environment. The company was co-founded in 2017 by Didier Toubia, The Kitchen Hub of the Strauss Group, and Professor Shulamit Levenberg from the Biomedical Engineering Faculty at the Technion - Israel Institute of Technology. The company’s vision is to provide unconditional nutrition for anyone, anytime, anywhere. For more information, follow Aleph Farms on Instagram, Twitter, Facebook or LinkedIn or visit www.aleph-farms.com. Access the Aleph Farms press kit here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005338/en/
Contact information
Lizi Sprague
alephfarms@songuepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IMEC Achieves a World-record GaN Breakdown Voltage Exceeding 650 V on Shin-Etsu Chemical’s 300-mm QST™ Substrate13.11.2025 06:00:00 EET | Press release
The QSTTM substrate*1, a 300-mm GaN growth substrate that Shin-Etsu Chemical Co., Ltd. (Head Office: Tokyo; President: Yasuhiko Saitoh; hereinafter, “Shin-Etsu Chemical”) developed, has been adopted for the 300-mm GaN power device development program at IMEC*2, where sample evaluation is in progress. In the evaluation, the 5 µm-thick HEMT*3 device using a QSTTM substrate achieved a record-breaking voltage resistance exceeding 650 V for a 300mm substrate. Shin-Etsu Chemical, licensed by QROMIS, Inc. (Head office: CA, U.S.A, CEO: Cem Basceri, hereafter "QROMIS"), manufactures 150-mm and 200-mm QST™ substrates, as well as GaN-on-QST™ epitaxial substrates of various diameters. In September 2024, we started providing 300-mm QST™ samples in a joint initiative with QROMIS. Furthermore, Shin-Etsu Chemical and QROMIS have established a close partnership to provide 300-mm QST™ substrates for the state-of-the-art 300-mm CMOS fab of IMEC, which is based in Leuven, Belgium. IMEC is a 300-mm GaN pow
DBS and Ant International Enhance Strategic Partnership to Scale Innovative Cross-Border Payment and Fintech Solutions to Drive Inclusive Growth13.11.2025 05:00:00 EET | Press release
DBS and Ant International have agreed to deepen their existing strategic collaboration to jointly explore innovative payments, digitisation and fintech solutions aimed at providing more inclusive services for regional businesses of all sizes and individual consumers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112714266/en/ From left to right: Tan Su Shan, CEO of DBS, Loy Hwee Chuan, Segment Head of Telecommunications, Media & Tech, Hong Kong and GBA, DBS, Edward Yue, Alipay+ General Manager for SEA, ANZ and South Asia at Ant International, Peng Yang, CEO of Ant International The collaboration will leverage DBS’ digital banking capabilities and Ant International’s cutting-edge financial technologies such as AI and blockchain, to scale cross-border payments, strengthen connectivity and drive innovations in the financial ecosystem. The Memorandum of Understanding (MoU) was inked on the sidelines of the Singapore Fintech
LabGenius Therapeutics Announces Poster Presentation at the ESMO Immuno-Oncology Congress 202513.11.2025 02:00:00 EET | Press release
LabGenius Therapeutics (“LabGenius”), a drug discovery company combining artificial intelligence (AI) and high-throughput experimentation to advance next-generation multispecific antibodies for solid tumours, today announced a scientific poster will be presented at the ESMO Immuno-Oncology Congress 2025, being held December 10 - 12, 2025, at the Queen Elizabeth II Centre in London, United Kingdom. LabGenius’ presentation will debut the pre-clinical in vivo efficacy (>90% tumour growth inhibition) and tolerability data for their lead asset, a highly tumour selective bispecific T-cell engager (TCE). Poster Presentation Details Title Novel Selectivity-Enhanced Bispecific T-cell Engager Utilises Avidity to Overcome On-target, Off-tumour Toxicity Date and time Wednesday, December 10, 2025, 08:00 (GMT) Poster number 309P Location The Churchill Room, Queen Elizabeth II Centre, London Bispecific TCE Overview For the selected target, LabGenius has developed a selectivity-enhanced TCE. The compa
VeriSilicon and Google Jointly Launch Open-Source Coral NPU IP13.11.2025 02:00:00 EET | Press release
VeriSilicon (688521.SH) recently announced the joint launch of the Coral NPU IP with Google, targeting always-on, ultra-low-energy edge Large Language Model (LLM) applications. The IP is based on Google’s foundational research in open machine learning compilers and enhanced with AI security features, providing developers with a unified open-source platform to build a robust edge AI ecosystem. The Coral NPU is built on the open RISC-V instruction set architecture, featuring native tensor processing capabilities, supporting mainstream machine learning frameworks such as JAX, PyTorch, and TensorFlow Lite (TFLite), and utilizing open-standard tools like Multi-Level Intermediate Representation (MLIR) from the Low Level Virtual Machine (LLVM) project for compiler infrastructure. It is designed for always-on, ultra-low-energy edge AI applications, particularly for wearable devices and ambient sensing systems. The Coral NPU IP is now open-sourced on the Google Developers website and available
Indero Announces Breakthrough Method for Early-Phase Evaluation of Topical Drugs Using Quantitative Gene Expression13.11.2025 01:00:00 EET | Press release
Indero is proud to announce the successful completion of an internally funded study that introduces a novel approach to evaluating topical new chemical entities (NCE) in early-phase clinical research. This innovative method leverages quantitative gene expression analysis to assess drug efficacy rapidly and cost effectively. Dr. Robert Bissonnette, Executive Chairman and Founder of Indero, who initiated and led the study, shared his excitement about the results: “Our goal was to rethink how to study topical drugs in early phase studies. The results of this study demonstrate that microdosing for only 3 days can provide meaningful efficacy signals. Within just 24 hours, we observed alterations in gene expression after applying a microdose of mid-potency corticosteroid on the skin of patients. By 72 hours, Th2, Th22 and Th17-specific biomarkers were significantly reduced. This outcome is exactly what we hoped for and opens the door to faster, smarter drug development strategies, demonstrat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
